Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Short Interest Down 32.1% in July

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totaling 4,850,861 shares, a decrease of 32.1% from the June 30th total of 7,142,803 shares. Based on an average daily trading volume, of 947,818 shares, the days-to-cover ratio is presently 5.1 days. Currently, 9.1% of the company’s stock are sold short.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB lifted its position in shares of Supernus Pharmaceuticals by 8.9% during the second quarter. Handelsbanken Fonder AB now owns 20,716 shares of the specialty pharmaceutical company’s stock valued at $964,000 after buying an additional 1,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of Supernus Pharmaceuticals by 2.0% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 90,213 shares of the specialty pharmaceutical company’s stock worth $4,196,000 after acquiring an additional 1,759 shares in the last quarter. Empowered Funds LLC purchased a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $264,000. Bank of America Corp DE lifted its position in Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after acquiring an additional 193,479 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in Supernus Pharmaceuticals by 26.9% in the first quarter. California State Teachers Retirement System now owns 67,686 shares of the specialty pharmaceutical company’s stock valued at $3,499,000 after acquiring an additional 14,347 shares in the last quarter.

Analyst Upgrades and Downgrades

SUPN has been the subject of several recent research reports. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $62.83.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $45.61 on Friday. The stock has a market capitalization of $2.65 billion, a P/E ratio of -89.43, a price-to-earnings-growth ratio of 1.00 and a beta of 0.54. Supernus Pharmaceuticals has a 1-year low of $32.83 and a 1-year high of $59.68. The business has a fifty day moving average price of $46.34 and a 200 day moving average price of $49.13.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.